This Week in Critical Care — Jul 29, 2026

Welcome to This Week in Critical Care. This week we're covering 4 notable papers spanning acute kidney injury biomarker reporting and cardiac arrest resuscitation and prognostication. Let's dive in.

Diagnostic accuracy in critical care relies heavily on the quality of biomarker studies, yet the literature has long been hindered by heterogeneity and poor adherence to reporting standards. In a systematic literature review published in Intensive Care Medicine, Yu and colleagues evaluated 122 diagnostic test accuracy studies for acute kidney injury biomarkers and found that compliance with the Standards for Reporting Diagnostic Accuracy checklist was too low to permit meta-analysis [1]. Only 19 studies reported on the diagnosis of acute kidney injury within 48 hours of sampling, and just 16 met high-quality criteria based on QUADAS-2 assessments [1]. To address this, an international expert panel convened via a modified Delphi process to establish STARDaki, a consensus-based extension of the STARD guidelines specifically tailored to standardize the reporting of acute kidney injury biomarker research, covering critical domains like patient selection, reference standards, and test-retest reliability [1]. For the clinician, this means that future biomarker literature may finally offer the transparent, generalizable estimates needed to guide bedside decision-making with confidence.

When we shift our focus to the management and post-resuscitation care of cardiac arrest, several new registry and observational insights shed light on both adult and pediatric cohorts. In a nationwide administrative study published in Resuscitation, Shiima and colleagues analyzed over 7 million pediatric admissions in Japan between 2011 and 2022 to evaluate the incidence and outcomes of pediatric in-hospital cardiac arrest [3]. Identifying nearly 7,000 cases through recorded chest compression procedure codes, the authors reported an overall in-hospital cardiac arrest incidence of 0.98 per 1,000 admissions, which declined modestly over the study period from 1.03 down to 0.86 [3]. Overall survival to hospital discharge was 30.6 percent, showing a statistically significant improvement from 25.8 percent in 2011 to 29.6 percent in 2022 [3]. Notably, adrenaline and tracheal intubation were recorded on the same day as chest compressions in the majority of cases, though the authors emphasize that administrative code-based ascertainment requires cautious interpretation and highlights the ongoing need for dedicated national resuscitation registries [3].

Looking upstream at out-of-hospital cardiac arrest, predicting initial rhythm remains vital for survival modeling. In a study published in Resuscitation, Ulusoy and colleagues linked the Danish Cardiac Arrest Registry with prior hospital-recorded electrocardiograms to examine how pre-existing electrocardiographic abnormalities relate to shockable initial rhythms [4]. Among over 11,000 bystander-witnessed arrests with available prior tracings, shockable rhythms occurred in roughly 22 percent of individuals with normal baseline electrocardiograms, compared to higher proportions in those with abnormalities [4]. Specifically, pathological Q-waves, left ventricular hypertrophy, atrial fibrillation, intraventricular conduction delay, and left bundle branch block were all associated with significantly increased odds of presenting with a shockable rhythm, with left bundle branch block roughly doubling the odds compared to normal electrocardiograms [4]. These findings suggest that outpatient electrocardiographic data can meaningfully identify patients more likely to present with a treatable rhythm should cardiac arrest occur [4].

Once a patient is successfully resuscitated from cardiac arrest, accurate neuroprognostication becomes paramount, though clinicians constantly grapple with potential confounding from the withdrawal of life-sustaining therapy. In a prospective observational multicenter study published in Critical Care, Goetze and colleagues evaluated guideline-recommended prognostic markers within 14 days after cardiac arrest among 101 adult patients who remained comatose at 72 hours but crucially had no withdrawal of life-sustaining therapy during the first four weeks [2]. Poor outcomes, defined as a modified Rankin Scale score of 4 to 6 at 12 months, occurred in 67.3 percent of these patients [2]. Individual markers demonstrated high specificity but limited sensitivity, while the presence of two or more unfavorable markers within 14 days yielded no false positives and was strongly associated with poor outcome [2]. Furthermore, adding the best Coma Recovery Scale-Revised score significantly improved prognostic discrimination compared to established markers alone, offering a valuable tool for cases of uncertain prognosis [2].

If you only have time for one paper this week, make it the prospective multicenter evaluation of neuroprognostication after cardiac arrest by Goetze and colleagues in Critical Care [2]. By strictly excluding patients who underwent early withdrawal of life-sustaining therapy, this study provides much-needed reassurance that multimodal prognostic testing maintains high specificity for poor long-term outcomes in comatose survivors [2].

Here are the key takeaways from this week in Critical Care. Acute kidney injury biomarker studies suffer from poor adherence to reporting standards, prompting the new consensus-based STARDaki criteria to improve future diagnostic accuracy research [1]. Pediatric in-hospital cardiac arrest incidence in Japan showed a slight decline over a decade, while overall survival to hospital discharge improved to approximately 30 percent [3]. Pre-existing electrocardiographic abnormalities such as left bundle branch block and atrial fibrillation are associated with higher odds of a shockable initial rhythm in bystander-witnessed out-of-hospital cardiac arrest [4]. In comatose cardiac arrest survivors without early withdrawal of life-sustaining therapy, multimodal prognostication using two or more unfavorable markers demonstrates high specificity for predicting poor 12-month outcomes, with additional benefit from serial Coma Recovery Scale-Revised assessments [2].

That's your roundup for This Week in Critical Care. The full transcript and references are available on the episode page in your AudioScholar library. This is an AI-curated summary — for clinical decisions, always consult primary sources and current guidelines. See you next week. One more note before you go: only 4 new papers of note met the bar since the last update — a quieter stretch for new literature. Still worth revisiting from recent updates: Sodium bicarbonate therapy in severe metabolic acidemia: an individual patient data meta-analysis of the BICAR-ICU and BICAR-ICU2 trials, in Critical care (London, England); and Hemoperfusion during extracorporeal membrane oxygenation: an updated systematic review and meta-analysis of 8,151 patients, in Critical care (London, England).

If this weekly briefing is useful, follow the show in your podcast app so new episodes arrive automatically. And if you have a paper you have been meaning to read, upload the PDF, or paste any link, at audioscholar dot C C. We will turn it into audio like this one, in any of thirty-one languages.

This is an automated summary generated by artificial intelligence, which can make mistakes. Always review the original source materials.